Photo taken from Agenus/LinkedIn
May 17, 2024, 11:18
Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA
Agenus shared on LinkedIn:
“Today we announced that Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA to discuss our botensilimab/balstilimab therapy for relapsed or refractory metastatic colorectal cancer.
Learn more.”
Source: Agenus/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 09:31
Nov 14, 2024, 09:26
Nov 14, 2024, 09:21
Nov 14, 2024, 09:15
Nov 14, 2024, 00:19